Acura Pharmaceuticals, Inc

Moat Score

Market Cap $130.64K
PE -0
Debt $0.00
Cash $65.00K
EV $65.64K
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$879.00K
EBIT	-$879.00K
ROE	-494%
ROA	-102%
Equity	$178.00K
Growth Stability	1
PE	-0.15
PB	0.73
P/S	0.08
Price/Cash	0.5
Debt/Equity	0
Net Margins	-56%
Op. Margins	-56%
Sales Growth YoY	-95%
Sales Growth QoQ	-87%
Sales CAGR	-11%
Equity CAGR	-11%
Earnings Growth YoY	-112%
Earnings Growth QoQ	-111%

Sales CAGR 5Y	6%
Equity CAGR 5Y	-10%
Earnings CAGR 3Y	81%
Sales CAGR 3Y	81%
Market Cap	$130.64K
Revenue	$1.56M
Assets	$860.00K
Total Debt	$0.00
Cash	$65.00K
Shares Outstanding	56.8M
EV	65.64K
Moat Score	1%
Working Capital	-143K
Current Ratio	0.72
Shares Growth 3y	41%
Equity Growth QoQ	32%
Equity Growth YoY	-103%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

SEC Filings

Direct access to Acura Pharmaceuticals, Inc (ACUR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2021
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2020
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2019
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Acura Pharmaceuticals, Inc compare to its competitors?

Not enough data to generate a comparison chart between Acura Pharmaceuticals, Inc and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Acura Pharmaceuticals, Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Acura Pharmaceuticals, Inc Discounted Cash Flow

Fully customizable DCF calculator online for Acura Pharmaceuticals, Inc.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	TTM
Net Margins	-2K%	-58%	-166%	-192%	-937%	-142%	-34%	-56%	-56%
ROA	-	-23%	-80%	-113%	-179%	-28%	-44%	-102%	-102%
ROE	-	-63%	-625%	21K%	106%	80%	21%	-494%	-494%

Bad Net Margins (-56.24%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	TTM
Debt over FCF	-	-2.66	-1.4	-1.2	-	-	-	-	-
Debt over Equity	2.33	1.31	6.66	-201.26	-1.17	-1.27	-2.04	0	0
Growth Stability	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	CAGR 5Y
Revenue YoY growth	-	1K%	-48%	-34%	-86%	548%	34%	-56%	6%
Earnings YoY growth	-	-62%	48%	-23%	-32%	-2%	-68%	-27%	-
Equity YoY growth	-	56%	-85%	-102%	13K%	31%	24%	-103%	-10%
FCF YoY growth	-	-65%	44%	-20%	-	-	-	-	-